Chiltern Director To Speak At Clinical Operations In Oncology Trials Conference

Scott Currence, director service partnership, early phase oncology development at Chiltern, a leading, global contract research organization, will speak at the Clinical Operations in Oncology Trials Conference Europe 2015 in Amsterdam, at 12:15 p.m. Dec. 1, 2015.

In his presentation, “Delivery of Complex Oncology Clinical Trials,” Currence will discuss developing effective study designs, strengthening team communication and implementing and conducting complex oncology trials. The presentation will also examine enrollment management and special operational considerations for emerging therapies.

“Planning a successful oncology trial begins with a cross-functional approach to selecting an appropriate study design,” Currence said. “Ask the right questions and engage your development team; complex trials can often be viewed in distinct segments simplifying operational planning and management.”

As a therapeutic leader for oncology studies at Chiltern, Currence has experience with all phases of clinical development, offering strategic guidance and oversight. He is one of Chiltern’s oncology specialists who first seek to understand customers’ requirements to deliver customized and comprehensive services.

Chiltern oncology teams have conducted hundreds of oncology trials in all phases of development, offering extensive services and deep expertise.

About Chiltern
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 3,700 works across 47 countries to provide comprehensive, yet flexible and responsive, services with specialties in Biopharma, Medical Device & Diagnostics, Oncology, Clinical Analytics and Source. For more information, visit Chiltern.com.